Click here to get full coverage on Understanding Momentum Shifts in (TRDA) - Stock Traders Daily

Understanding Momentum Shifts in (TRDA)  Stock Traders Daily

Understanding Momentum Shifts in (TRDA) - Stock Traders Daily

Click here to get full coverage on Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView

Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA  TradingView

Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView

Click here to get full coverage on Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives - simplywall.st

Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives  simplywall.st

Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives - simplywall.st

Click here to get full coverage on $TRDA stock is down 55% today. Here's what we see in our data. - Quiver Quantitative

$TRDA stock is down 55% today. Here's what we see in our data.  Quiver Quantitative

$TRDA stock is down 55% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm  GlobeNewswire

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Click here to get full coverage on TRDA - Entrada Therapeutics Inc Stock Price and Quote - Finviz

TRDA - Entrada Therapeutics Inc Stock Price and Quote  Finviz

TRDA - Entrada Therapeutics Inc Stock Price and Quote - Finviz

Click here to get full coverage on Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan

Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options  Stock Titan

Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan

Click here to get full coverage on Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?  Yahoo Finance

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily

Discipline and Rules-Based Execution in TRDA Response  Stock Traders Daily

Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily

Click here to get full coverage on Entrada posts early Duchenne benefit, says cash lasts into Q3 2027 - Stock Titan

Entrada posts early Duchenne benefit, says cash lasts into Q3 2027  Stock Titan

Entrada posts early Duchenne benefit, says cash lasts into Q3 2027 - Stock Titan

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily

Avoiding Lag: Real-Time Signals in (TRDA) Movement  Stock Traders Daily

Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily

Click here to get full coverage on TRDA Forecast — Price Target — Prediction for 2027 - TradingView

TRDA Forecast — Price Target — Prediction for 2027  TradingView

TRDA Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView

Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)  TradingView

Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView

Click here to get full coverage on TRDA: All proposals, including director elections and plan amendments, were approved by stockholders - TradingView

TRDA: All proposals, including director elections and plan amendments, were approved by stockholders  TradingView

TRDA: All proposals, including director elections and plan amendments, were approved by stockholders - TradingView

Click here to get full coverage on Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan

Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading  Stock Titan

Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA - PR Newswire

Click here to get full coverage on Insider Purchase: Director at $TRDA Buys 5,000 Shares - Quiver Quantitative

Insider Purchase: Director at $TRDA Buys 5,000 Shares  Quiver Quantitative

Insider Purchase: Director at $TRDA Buys 5,000 Shares - Quiver Quantitative

Click here to get full coverage on Market Movers | Winners: BNZI, OLOX, AGL | Losers: GDC, ENGN, TRDA - Trefis

Market Movers | Winners: BNZI, OLOX, AGL | Losers: GDC, ENGN, TRDA  Trefis

Market Movers | Winners: BNZI, OLOX, AGL | Losers: GDC, ENGN, TRDA - Trefis

Click here to get full coverage on Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review

Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir  The National Law Review

Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review

Click here to get full coverage on Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline  Finviz

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz

Click here to get full coverage on INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC  GlobeNewswire

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire

Click here to get full coverage on Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan

Rare disease trial tests DMD treatment with once-every-six-week dosing  Stock Titan

Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan

Click here to get full coverage on Income Statement - Intellectia AI

Income Statement - Intellectia AI

Click here to get full coverage on Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily

Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones  Stock Traders Daily

Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily

Click here to get full coverage on $TRDA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

$TRDA stock is up 7% today. Here's what we see in our data.  Quiver Quantitative

$TRDA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution  TradingKey

Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Click here to get full coverage on TRDA Winners Celebration 2025 - Graduate Studies - Trinity College Dublin

TRDA Winners Celebration 2025 - Graduate Studies  Trinity College Dublin

TRDA Winners Celebration 2025 - Graduate Studies - Trinity College Dublin

Click here to get full coverage on Entrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial Position - Quiver Quantitative

Entrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial Position  Quiver Quantitative

Entrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial Position - Quiver Quantitative

Click here to get full coverage on 5/7/2026 Market Update - Winners: BNZI, OLOX, AGL - Losers: GDC, ENGN, TRDA - S&P 500: -0.4% - Trefis

5/7/2026 Market Update - Winners: BNZI, OLOX, AGL - Losers: GDC, ENGN, TRDA - S&P 500: -0.4%  Trefis

5/7/2026 Market Update - Winners: BNZI, OLOX, AGL - Losers: GDC, ENGN, TRDA - S&P 500: -0.4% - Trefis

Click here to get full coverage on Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report  simplywall.st

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

Click here to get full coverage on Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com

Entrada Therapeutics president & COO sells $229,953 in shares  Investing.com

Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com

Click here to get full coverage on Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView

Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026  TradingView

Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView

Click here to get full coverage on Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire

Entrada Therapeutics, Inc. Shareholders Are Encouraged to  GlobeNewswire

Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire

Click here to get full coverage on Entrada Therapeutics to report phase 1/2 trial data Thursday - Investing.com

Entrada Therapeutics to report phase 1/2 trial data Thursday  Investing.com

Entrada Therapeutics to report phase 1/2 trial data Thursday - Investing.com

Click here to get full coverage on TRDA Q1 2026 Earnings: Beat on Losses but No Revenue – Pre-Revenue Biotech Shows Cost Discipline - Post-Earnings Drift - dars.gov.et

TRDA Q1 2026 Earnings: Beat on Losses but No Revenue – Pre-Revenue Biotech Shows Cost Discipline - Post-Earnings Drift  dars.gov.et

TRDA Q1 2026 Earnings: Beat on Losses but No Revenue – Pre-Revenue Biotech Shows Cost Discipline - Post-Earnings Drift - dars.gov.et

Click here to get full coverage on TRDA | Entrada Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative

TRDA | Entrada Therapeutics, Inc. Common Analyst Forecasts  Quiver Quantitative

TRDA | Entrada Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative

Click here to get full coverage on Entrada shares sink after Duchenne drug falls short of expectations - marketscreener.com

Entrada shares sink after Duchenne drug falls short of expectations  marketscreener.com

Entrada shares sink after Duchenne drug falls short of expectations - marketscreener.com

Click here to get full coverage on Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - Moomoo

Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating  Moomoo

Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - Moomoo

Click here to get full coverage on Meet Dwayne Allen - CanvasRebel Magazine

Meet Dwayne Allen  CanvasRebel Magazine

Meet Dwayne Allen - CanvasRebel Magazine

Click here to get full coverage on TRDA Q1 2026 Earnings: Narrower Than Expected Loss Lifts Shares as Pipeline Advances - ROA Comparison - dars.gov.et

TRDA Q1 2026 Earnings: Narrower Than Expected Loss Lifts Shares as Pipeline Advances - ROA Comparison  dars.gov.et

TRDA Q1 2026 Earnings: Narrower Than Expected Loss Lifts Shares as Pipeline Advances - ROA Comparison - dars.gov.et

Click here to get full coverage on TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 - Investing.com

TD Cowen analyst highlights 10+ potential biotech catalysts for 2026  Investing.com

TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 - Investing.com

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 - The Manila Times

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026  The Manila Times

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 - The Manila Times

Click here to get full coverage on Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView

Entrada Therapeutics, Inc. SEC 10-Q Report  TradingView

Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on TRDA Stock Price and Chart — NASDAQ:TRDA - TradingView

TRDA Stock Price and Chart — NASDAQ:TRDA  TradingView

TRDA Stock Price and Chart — NASDAQ:TRDA - TradingView

Click here to get full coverage on Entrada Therapeutics (TRDA) Stock Forecast and Price Target 2026 $TRDA - MarketBeat

Entrada Therapeutics (TRDA) Stock Forecast and Price Target 2026 $TRDA  MarketBeat

Entrada Therapeutics (TRDA) Stock Forecast and Price Target 2026 $TRDA - MarketBeat

Click here to get full coverage on Insider Sale: Chief Financial Officer of $TRDA (TRDA) Sells 1,000 Shares - Quiver Quantitative

Insider Sale: Chief Financial Officer of $TRDA (TRDA) Sells 1,000 Shares  Quiver Quantitative

Insider Sale: Chief Financial Officer of $TRDA (TRDA) Sells 1,000 Shares - Quiver Quantitative

Click here to get full coverage on TRDA Group Project Award - School of Linguistic, Speech and Communication Sciences - Trinity College Dublin

TRDA Group Project Award - School of Linguistic, Speech and Communication Sciences  Trinity College Dublin

TRDA Group Project Award - School of Linguistic, Speech and Communication Sciences - Trinity College Dublin

Click here to get full coverage on TRDA Stock Price, News & Analysis - Stock Titan

TRDA Stock Price, News & Analysis  Stock Titan

TRDA Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA - PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA  PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA - PR Newswire

Click here to get full coverage on PI Only Winners 2024 2025 - Graduate Studies - Trinity College Dublin

PI Only Winners 2024 2025 - Graduate Studies  Trinity College Dublin

PI Only Winners 2024 2025 - Graduate Studies - Trinity College Dublin

Click here to get full coverage on TRDA hosting small business summit, boot camp Shark Tank style - Tahlequah Daily Press

TRDA hosting small business summit, boot camp Shark Tank style  Tahlequah Daily Press

TRDA hosting small business summit, boot camp Shark Tank style - Tahlequah Daily Press

Click here to get full coverage on Entrada Therapeutics Stock Price Forecast. Should You Buy TRDA? - StockInvest.us

Entrada Therapeutics Stock Price Forecast. Should You Buy TRDA?  StockInvest.us

Entrada Therapeutics Stock Price Forecast. Should You Buy TRDA? - StockInvest.us

Click here to get full coverage on Should I buy Entrada Therapeutics (TRDA) - Zacks Investment Research

Should I buy Entrada Therapeutics (TRDA)  Zacks Investment Research

Should I buy Entrada Therapeutics (TRDA) - Zacks Investment Research

Click here to get full coverage on Entrada Therapeutics (TRDA) Stock Price, News & Analysis $TRDA - MarketBeat

Entrada Therapeutics (TRDA) Stock Price, News & Analysis $TRDA  MarketBeat

Entrada Therapeutics (TRDA) Stock Price, News & Analysis $TRDA - MarketBeat

Click here to get full coverage on Vivo V60 India Launch Teased; Reportedly Spotted on TRDA Certification Site - Gadgets 360

Vivo V60 India Launch Teased; Reportedly Spotted on TRDA Certification Site  Gadgets 360

Vivo V60 India Launch Teased; Reportedly Spotted on TRDA Certification Site - Gadgets 360

Click here to get full coverage on TRDA Stock Price | Analyst Target 17.00 & Strong Buy Consensus - eToro

TRDA Stock Price | Analyst Target 17.00 & Strong Buy Consensus  eToro

TRDA Stock Price | Analyst Target 17.00 & Strong Buy Consensus - eToro

Click here to get full coverage on Tarapith Rampurhat Development Authority area to get extended - The Times of India

Tarapith Rampurhat Development Authority area to get extended  The Times of India

Tarapith Rampurhat Development Authority area to get extended - The Times of India

Click here to get full coverage on Vivo’s Galaxy S25 Edge lookalike spotted on certification site with 5380mAh battery - Gizmochina

Vivo’s Galaxy S25 Edge lookalike spotted on certification site with 5380mAh battery  Gizmochina

Vivo’s Galaxy S25 Edge lookalike spotted on certification site with 5380mAh battery - Gizmochina

Click here to get full coverage on Motorola Edge 50 Pro bags multiple certifications, including FCC, BIS and TRDA - Gizmochina

Motorola Edge 50 Pro bags multiple certifications, including FCC, BIS and TRDA  Gizmochina

Motorola Edge 50 Pro bags multiple certifications, including FCC, BIS and TRDA - Gizmochina

Click here to get full coverage on POCO F4 spotted on TRDA certification site, global launch expected soon - Gizmochina

POCO F4 spotted on TRDA certification site, global launch expected soon  Gizmochina

TRDA

Price Chart

Key Statistics

Technicals

About TRDA

Latest News

Understanding Momentum Shifts in (TRDA) - Stock Traders Daily

Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers